Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis. (Q35840984)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26566246%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

meta-analysis

0 references

title

Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26566246%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

1 reference

1 reference

1 reference

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26566246%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Essa A Mohamed

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26566246%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

Anna S F Lok

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26566246%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Brian J McMahon

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26566246%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Robert S Brown

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26566246%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

John B Wong

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26566246%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Ahmed T Ahmed

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26566246%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Wigdan Farah

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26566246%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Jehad Almasri

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26566246%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Khalid Benkhadra

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26566246%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Mohamed A Mouchli

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26566246%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Siddharth Singh

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26566246%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Abd Moain Abu Dabrh

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26566246%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Larry J Prokop

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26566246%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Zhen Wang

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26566246%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Mohammad Hassan Murad

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26566246%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Khaled Mohammed

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26566246%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

language of work or name

English

0 references

publication date

13 November 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26566246%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26566246%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

volume

63

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26566246%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26566246%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

284-306

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26566246%20AND%20SRC:MED&resulttype=core&format=json

Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity

29 February 2020

cites work

1 reference

The prevalence of hepatitis B virus infection in the United States in the era of vaccination

21 January 2018

1 reference

Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin

21 January 2018

1 reference

21 January 2018

1 reference

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

How to read a systematic review and meta-analysis and apply the results to patient care: users' guides to the medical literature

21 January 2018

1 reference

Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials

21 January 2018

1 reference

Randomised controlled trial of lymphoblastoid interferon for chronic active hepatitis B.

21 January 2018

1 reference

Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma

21 January 2018

1 reference

Comparison of long-term effects of lymphoblastoid interferon alpha and recombinant interferon alpha-2a therapy in patients with chronic hepatitis B.

21 January 2018

1 reference

The long-term course of chronic hepatitis B.

21 January 2018

1 reference

Influence of viral load and genotype in the progression of Hepatitis B-associated liver cirrhosis to hepatocellular carcinoma

21 January 2018

1 reference

Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study

21 January 2018

1 reference

The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. The Long-Term Follow-up Investigator Group. The European Study Group on Viral Hepatitis (EUROHEP). Executive Team on Anti-Viral Treatment.

21 January 2018

1 reference

Factors associated with progression to hepatocellular carcinoma and to death from liver complications in patients with HBsAg-positive cirrhosis

21 January 2018

1 reference

Course of disease and survival after onset of decompensation in hepatitis B virus-related cirrhosis

21 January 2018

1 reference

Nucleoside analogue can improve the long-term prognosis of patients with hepatitis B virus infection-associated acute on chronic liver failure.

21 January 2018

1 reference

The role of lamivudine and predictors of mortality in severe flare-up of chronic hepatitis B with jaundice.

21 January 2018

1 reference

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

21 January 2018

1 reference

Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection

21 January 2018

1 reference

Lamivudine for patients with chronic hepatitis B and advanced liver disease

21 January 2018

1 reference

Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients

21 January 2018

1 reference

Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure

21 January 2018

1 reference

Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease.

21 January 2018

1 reference

Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis

21 January 2018

1 reference

Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection

21 January 2018

1 reference

Entecavir improves the outcome of acute-on-chronic liver failure due to the acute exacerbation of chronic hepatitis B.

21 January 2018

1 reference

Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study

21 January 2018

1 reference

Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population

21 January 2018

1 reference

Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis

21 January 2018

1 reference

Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis.

21 January 2018

1 reference

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study.

21 January 2018

1 reference

Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine.

21 January 2018

1 reference

Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation

21 January 2018

1 reference

Entecavir vs lamivudine therapy for naïve patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure

21 January 2018

1 reference

Early entecavir treatment for chronic hepatitis B with severe acute exacerbation

21 January 2018

1 reference

Comparing the efficacy and clinical outcome of telbivudine and entecavir naïve patients with hepatitis B virus-related compensated cirrhosis

21 January 2018

1 reference

Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis

21 January 2018

1 reference

Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.

21 January 2018

1 reference

Effect of Peg-interferon α-2a combined with Adefovir in HBV postpartum women with normal levels of ALT and high levels of HBV DNA.

21 January 2018

1 reference

High frequency of recurrent viremia after hepatitis B e antigen seroconversion and consolidation therapy

21 January 2018

1 reference

The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion.

21 January 2018

1 reference

Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease.

21 January 2018

1 reference

Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naïve patients with chronic hepatitis B: a multicenter real-life study

21 January 2018

1 reference

Tenofovir versus entecavir in treatment of chronic hepatitis B virus with severe acute exacerbation

21 January 2018

1 reference

Effect of nucleoside and nucleotide analogues on renal function in patients with chronic hepatitis B virus monoinfection.

21 January 2018

1 reference

Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B.

21 January 2018

1 reference

21 January 2018

1 reference

Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load

21 January 2018

1 reference

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

21 January 2018

1 reference

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

21 January 2018

1 reference

Chronic hepatitis B: update 2009

21 January 2018

1 reference

The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B

21 January 2018

1 reference

7 January 2021

Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B

1 reference

7 January 2021

Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis

1 reference

7 January 2021

Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study

1 reference

7 January 2021

Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP)

1 reference

7 January 2021

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

7 January 2021

Prognosis of hepatitis B-related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents

1 reference

7 January 2021

Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure

1 reference

7 January 2021

Entecavir versus lamivudine in the treatment of chronic hepatitis B patients with hepatic decompensation

1 reference

7 January 2021

Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B

1 reference

7 January 2021

Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos(t)ide-naive patients with chronic hepatitis B

1 reference

7 January 2021

Long-term treatment with tenofovir in Asian-American chronic hepatitis B patients is associated with abnormal renal phosphate handling

1 reference

7 January 2021

Risk and predictors of mortality associated with chronic hepatitis B infection

1 reference

7 January 2021

AASLD guidelines for treatment of chronic hepatitis B.

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.28280

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26566246%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26566246%20AND%20SRC:MED&resulttype=core&format=json